Free Trial
→ Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next (From Paradigm Press) (Ad)tc pixel Free TTRX Stock Alerts

Turn Therapeutics (TTRX) Competitors

Turn Therapeutics logo
$3.92 +0.04 (+0.90%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

TTRX vs. AVIR, ENTA, BNTC, LRMR, and MNPR

Should you buy Turn Therapeutics stock or one of its competitors? MarketBeat compares Turn Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Turn Therapeutics include Atea Pharmaceuticals (AVIR), Enanta Pharmaceuticals (ENTA), Benitec Biopharma (BNTC), Larimar Therapeutics (LRMR), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry.

How does Turn Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

In the previous week, Turn Therapeutics had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 2 mentions for Turn Therapeutics and 1 mentions for Atea Pharmaceuticals. Turn Therapeutics' average media sentiment score of 1.47 beat Atea Pharmaceuticals' score of 0.62 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Atea Pharmaceuticals Positive
Turn Therapeutics Positive

Turn Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Atea PharmaceuticalsN/A -46.34% -42.52%
Turn Therapeutics N/A N/A N/A

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 18.1% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Turn Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/A-$158.35M-$1.94N/A
Turn TherapeuticsN/AN/A-$3.19M-$0.16N/A

Turn Therapeutics has a consensus target price of $8.00, indicating a potential upside of 104.34%. Given Turn Therapeutics' higher possible upside, analysts plainly believe Turn Therapeutics is more favorable than Atea Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atea Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Turn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Turn Therapeutics beats Atea Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Turn Therapeutics compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Turn Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Turn Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enanta Pharmaceuticals$65.32M6.35-$81.89M-$3.20N/A
Turn TherapeuticsN/AN/A-$3.19M-$0.16N/A

Enanta Pharmaceuticals presently has a consensus price target of $20.29, indicating a potential upside of 41.86%. Turn Therapeutics has a consensus price target of $8.00, indicating a potential upside of 104.34%. Given Turn Therapeutics' higher possible upside, analysts clearly believe Turn Therapeutics is more favorable than Enanta Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enanta Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Turn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Turn Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -106.80%. Turn Therapeutics' return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Enanta Pharmaceuticals-106.80% -78.58% -23.18%
Turn Therapeutics N/A N/A N/A

In the previous week, Enanta Pharmaceuticals and Enanta Pharmaceuticals both had 2 articles in the media. Turn Therapeutics' average media sentiment score of 1.47 beat Enanta Pharmaceuticals' score of 0.98 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Enanta Pharmaceuticals Positive
Turn Therapeutics Positive

Summary

Turn Therapeutics beats Enanta Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Turn Therapeutics compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Benitec Biopharma currently has a consensus price target of $27.00, suggesting a potential upside of 124.79%. Turn Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 104.34%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Turn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Benitec Biopharma
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Turn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Benitec Biopharma had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 4 mentions for Benitec Biopharma and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 1.47 beat Benitec Biopharma's score of 0.62 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Benitec Biopharma Positive
Turn Therapeutics Positive

52.2% of Benitec Biopharma shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Turn Therapeutics' return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Benitec BiopharmaN/A -38.92% -37.68%
Turn Therapeutics N/A N/A N/A

Turn Therapeutics has lower revenue, but higher earnings than Benitec Biopharma. Turn Therapeutics is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benitec Biopharma$80K5,157.22-$37.92M-$1.14N/A
Turn TherapeuticsN/AN/A-$3.19M-$0.16N/A

Summary

Benitec Biopharma beats Turn Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Turn Therapeutics compare to Larimar Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

91.9% of Larimar Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Turn Therapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Turn TherapeuticsN/A N/A N/A
Larimar Therapeutics N/A -137.70%-101.43%

Turn Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Turn TherapeuticsN/AN/A-$3.19M-$0.16N/A
Larimar TherapeuticsN/AN/A-$165.67M-$2.21N/A

In the previous week, Turn Therapeutics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 2 mentions for Turn Therapeutics and 1 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.89 beat Turn Therapeutics' score of 1.47 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Turn Therapeutics Positive
Larimar Therapeutics Very Positive

Turn Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 104.34%. Larimar Therapeutics has a consensus target price of $16.50, indicating a potential upside of 295.21%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than Turn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Turn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Larimar Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10

Summary

Larimar Therapeutics beats Turn Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Turn Therapeutics compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

1.8% of Monopar Therapeutics shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Turn Therapeutics' return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Monopar TherapeuticsN/A -14.24% -13.93%
Turn Therapeutics N/A N/A N/A

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Turn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monopar TherapeuticsN/AN/A-$13.72M-$1.82N/A
Turn TherapeuticsN/AN/A-$3.19M-$0.16N/A

Monopar Therapeutics presently has a consensus price target of $107.00, indicating a potential upside of 73.76%. Turn Therapeutics has a consensus price target of $8.00, indicating a potential upside of 104.34%. Given Turn Therapeutics' higher probable upside, analysts clearly believe Turn Therapeutics is more favorable than Monopar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monopar Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00
Turn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Monopar Therapeutics and Monopar Therapeutics both had 2 articles in the media. Turn Therapeutics' average media sentiment score of 1.47 beat Monopar Therapeutics' score of 0.97 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Monopar Therapeutics Positive
Turn Therapeutics Positive

Summary

Turn Therapeutics beats Monopar Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Turn Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TTRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TTRX vs. The Competition

Export
MetricTurn TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$116.63M$895.26M$4.26B$12.13B
Dividend YieldN/A4.84%5.78%5.23%
P/E Ratio-24.471.5823.5025.45
Price / SalesN/A118.14150.3175.37
Price / CashN/A20.0749.5336.29
Price / Book24.477.6236.536.64
Net Income-$3.19M-$3.77M$114.78M$333.40M
7 Day Performance5.81%57.29%0.46%-0.45%
1 Month Performance16.87%49.23%4.51%7.83%
1 Year PerformanceN/A104.84%20.27%35.63%

Turn Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TTRX
Turn Therapeutics
3.3709 of 5 stars		$3.92
+0.9%		$8.00
+104.3%		N/A$116.63MN/AN/A2
AVIR
Atea Pharmaceuticals
0.8193 of 5 stars		$5.54
-1.9%		N/A+98.9%$452.15MN/AN/A70
ENTA
Enanta Pharmaceuticals
1.9262 of 5 stars		$15.09
-1.0%		$20.29
+34.4%		+193.4%$442.25M$66.98MN/A160
BNTC
Benitec Biopharma
2.0234 of 5 stars		$12.14
-3.4%		$27.67
+127.9%		-12.1%$431.83M$80KN/A20
LRMR
Larimar Therapeutics
4.1778 of 5 stars		$4.00
-3.6%		$16.50
+312.5%		+92.9%$431.11MN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TTRX) was last updated on 5/12/2026 by MarketBeat.com Staff.
From Our Partners
NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for NV-387, its antiviral candidate targe...
Equiscreen | Sponsoredtc pixel
If You Have $50k+ on Coinbase, This Will Ruin Your Day
In 2009, Greece's debt-to-GDP ratio hit 130%. Within 24 months... Pensions were slashed 40% overnight. Bank ac...
Decentralized Masters | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Rise of the… petroyuan?
On February 28th, Iran installed a yuan-denominated toll at the Strait of Hormuz - the chokepoint for one in e...
Golden Portfolio | Sponsoredtc pixel
Nevada gold explorer near Kinross district draws attention
Gold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...
Wall Street Logic | Sponsoredtc pixel
Read this or regret it forever
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel